Читать книгу Hyperandrogenism in Women - Группа авторов - Страница 38

1Schiffer L, Arlt W, Storbeck KH: Intracrine androgen biosynthesis, metabolism and action revisited. Mol Cell Endocrinol 2018;465:4–26.

2Giagulli VA, Giorgino R, Vermeulen A: Is plasma 5 alpha-androstane 3 alpha, 17 beta-diol glucuronide a biochemical marker of hirsutism in women? J Steroid Biochem Mol Biol 1991;39:55–61.

3Bélanger C, Luu-The V, Dupont P, Tchernof A: Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res 2002;34:737–745.

4Burger HG: Androgen production in women. Fertil Steril 2002;77(suppl 4):S3–S5.

5Miller WL, Auchus RJ: The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011;32:81–151.

6Isidori AM, Balercia G, Calogero AE, Corona G, Ferlin A, Francavilla S, et al: Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest 2015;38:103–112.

7Toomey CM, Cremona A, Hughes K, Norton C: A review of body composition measurement in the assessment of health. Top Clin Nutr 2015;30:16–32.

8Nuttall FQ: Body mass index: obesity, BMI, and health: a critical review. Nutr Today 2015;50:117–128.

9Shah NR, Braverman ER: Measuring adiposity in patients: the utility of body mass index (BMI), percent body fat, and leptin. PLoS One 2012;7:e33308.

10Lam BC, Koh GC, Chen C, Wong MT, Fallows SJ: Comparison of body mass index (BMI), body adiposity index (BAI), waist circumference (WC), waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR) as predictors of cardiovascular disease risk factors in an adult population in Singapore. PLoS One 2015;10:e0122985.

11Escobar-Morreale HF, Alvarez-Blasco F, Botella-Carretero JI, Luque-Ramírez M: The striking similarities in the metabolic associations of female androgen excess and male androgen deficiency. Hum Reprod 2014;29:2083–2091.

12Seyfart T, Friedrich N, Kische H, Bülow R, Wallaschofski H, Völzke H, et al: Association of sex hormones with physical, laboratory, and imaging markers of anthropometry in men and women from the general population. PLoS One 2018;13:e0189042.

13Lee SY, Gallagher D: Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care 2008;11:566–572.

14Geer EB, Shen W: Gender differences in insulin resistance, body composition, and energy balance. Gend Med 2009;6(suppl 1):60–75.

15Blouin K, Veilleux A, Luu-The V, Tchernof A: Androgen metabolism in adipose tissue: recent advances. Mol Cell Endocrinol 2009;301:97–103.

16Santosa S, Jensen MD: Sex and sex steroids: impact on the kinetics of fatty acids underlying body shape. Horm Mol Biol Clin Investig 2014;20:15–23.

17Pasquali R, Gambineri A: A comprehensive approach in diagnosing the polycystic ovary syndrome. Womens Health 2015;11:501–512.

18Lovejoy JC, Bray GA, Bourgeois MO, Macchiavelli R, Rood JC, Greeson C, et al: Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women – a clinical research center study. J Clin Endocrinol Metab 1996;81:2198–2203.

19Allan CA, McLachlan RI: Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 2010;17:224–232.

20Giagulli VA, Kaufman JM, Vermeulen A: Pathogenesis of the decreased androgen levels in obese men. J Clin Endocrinol Metab 1994;79:997–1000.

21Gravholt CH, Jensen AS, Høst C, Bojesen A: Body composition, metabolic syndrome and type 2 diabetes in Klinefelter syndrome. Acta Paediatr 2011;100:871–877.

22Cheung AS, Hoermann R, Dupuis P, Joon DL, Zajac JD, Grossmann M: Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer. Eur J Endocrinol 2016;175:229–237.

23Storer TW, Miciek R, Travison TG: Muscle function, physical performance and body composition changes in men with prostate cancer undergoing androgen deprivation therapy. Asian J Androl 2012;14:204–221.

24Collins L, Basaria S: Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications. Asian J Androl 2012;14:222–225.

25Santosa S, Khosla S, McCready LK, Jensen MD: Effects of estrogen and testosterone on resting energy expenditure in older men. Obesity (Silver Spring) 2010;18:2392–2394.

26Chao J, Rubinow KB, Kratz M, Amory JK, Matsumoto AM, Page ST: Short-term estrogen withdrawal increases adiposity in healthy men. J Clin Endocrinol Metab 2016;101:3724–3731.

27Vandewalle S, Taes Y, Fiers T, Toye K, Van Caenegem E, Roggen I, et al: Associations of sex steroids with bone maturation, bone mineral density, bone geometry, and body composition: a cross-sectional study in healthy male adolescents. J Clin Endocrinol Metab 2014;99:E1272–E1282.

28Vandewalle S, Taes Y, Fiers T, Van Helvoirt M, Debode P, Herregods N, et al: Sex steroids in relation to sexual and skeletal maturation in obese male adolescents. J Clin Endocrinol Metab 2014;99:2977–2985.

29Dieudonne MN, Pecquery R, Leneveu MC, Giudicelli Y: Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2. Endocrinology 2000;141:649–656.

30Blouin K, Boivin A, Tchernof A: Androgens and body fat distribution. J Steroid Biochem Mol Biol 2008;108:272–280.

31Blouin K, Nadeau M, Perreault M, Veilleux A, Drolet R, Marceau P, et al: Effects of androgens on adipocyte differentiation and adipose tissue explant metabolism in men and women. Clin Endocrinol (Oxf) 2010;72:176–188.

32Xu X, De Pergola G, Björntorp P: The effects of androgens on the regulation of lipolysis in adipose precursor cells. Endocrinology 1990;126:1229–1234.

33Dubois V, Laurent MR, Jardi F, Antonio L, Lemaire K, Goyvaerts L, et al: Androgen deficiency exacerbates high-fat diet-induced metabolic alterations in male mice. Endocrinology 2016;157:648–665.

34O’Connell MD, Wu FC: Androgen effects on skeletal muscle: implications for the development and management of frailty. Asian J Androl 2014;16:203–212.

35Chusyd DE, Wang D, Huffman DM, Nagy TR: Relationships between rodent white adipose fat pads and human white adipose fat depots. Front Nutr 2016;3:10.

36Dieudonne MN, Pecquery R, Boumediene A, Leneveu MC, Giudicelli Y: Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. Am J Physiol 1998;274(6 Pt 1):C1645–C1652.

37Lacasa D, Garcia E, Henriot D, Agli B, Giudicelli Y: Site-related specificities of the control by androgenic status of adipogenesis and mitogen-activated protein kinase cascade/c-fos signaling pathways in rat preadipocytes. Endocrinology 1997;138:3181–3186.

38James RG, Krakower GR, Kissebah AH: Influence of androgenicity on adipocytes and precursor cells in female rats. Obes Res 1996;4:463–470.

39Elbers JM, de Jong S, Teerlink T, Asscheman H, Seidell JC, Gooren LJ: Changes in fat cell size and in vitro lipolytic activity of abdominal and gluteal adipocytes after a one-year cross-sex hormone administration in transsexuals. Metabolism 1999;48:1371–1377.

40Rodriguez-Cuenca S, Monjo M, Proenza AM, Roca P: Depot differences in steroid receptor expression in adipose tissue: possible role of the local steroid milieu. Am J Physiol Endocrinol Metab 2005;288:E200–E207.

41Veilleux A, Côté JA, Blouin K, Nadeau M, Pelletier M, Marceau P, et al: Glucocorticoid-induced androgen inactivation by aldo-keto reductase 1C2 promotes adipogenesis in human preadipocytes. Am J Physiol Endocrinol Metab 2012;302:E941–E949.

42Beilin J, Ball EM, Favaloro JM, Zajac JD: Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J Mol Endocrinol 2000;25:85–96.

43Pausova Z, Abrahamowicz M, Mahboubi A, Syme C, Leonard GT, Perron M, et al: Functional variation in the androgen-receptor gene is associated with visceral adiposity and blood pressure in male adolescents. Hypertension 2010;55:706–714.

44De Naeyer H, Bogaert V, De Spaey A, Roef G, Vandewalle S, Derave W, et al: Genetic variations in the androgen receptor are associated with steroid concentrations and anthropometrics but not with muscle mass in healthy young men. PLoS One 2014;9:e86235.

45Lapauw B, Goemaere S, Crabbe P, Kaufman JM, Ruige JB: Is the effect of testosterone on body composition modulated by the androgen receptor gene CAG repeat polymorphism in elderly men? Eur J Endocrinol 2007;156:395–401.

46Nielsen TL, Hagen C, Wraae K, Bathum L, Larsen R, Brixen K, et al: The impact of the CAG repeat polymorphism of the androgen receptor gene on muscle and adipose tissues in 20-29-year-old Danish men: Odense Androgen Study. Eur J Endocrinol 2010;162:795–804.

47Ibrahim MM: Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev 2010;11:11–18.

48Quinkler M, Sinha B, Tomlinson JW, Bujalska IJ, Stewart PM, Arlt W: Androgen generation in adipose tissue in women with simple obesity–a site-specific role for 17beta-hydroxysteroid dehydrogenase type 5. J Endocrinol 2004;183:331–342.

49O’Reilly MW, Kempegowda P, Walsh M, Taylor AE, Manolopoulos KN, Allwood JW, et al: AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2017;102:3327–3339.

50Hazlehurst JM, Oprescu AI, Nikolaou N, Di Guida R, Grinbergs AE, Davies NP, et al: Dual-5α-reductase inhibition promotes hepatic lipid accumulation in man. J Clin Endocrinol Metab 2016;101:103–113.

51Giagulli VA, De Pergola G, Giorgino F, Cignarelli M, Abbaticchio G, Vermeulen A, et al: Increased free testosterone but normal 5 alpha-reduced testosterone metabolites in obese premenopausal women. Clin Endocrinol (Oxf) 1992;36:553–558.

52Fassnacht M, Schlenz N, Schneider SB, Wudy SA, Allolio B, Arlt W: Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:2760–2766.

53Vassiliadi DA, Barber TM, Hughes BA, McCarthy MI, Wass JA, Franks S, et al: Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009;94:3558–366.

54Vandenput L, Mellström D, Lorentzon M, Swanson C, Karlsson MK, Brandberg J, et al: Androgens and glucuronidated androgen metabolites are associated with metabolic risk factors in men. J Clin Endocrinol Metab 2007;92:4130–4137.

55Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC: Plasma precursors of estrogen. II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 1974;38:476–479.

56Eyster KM: The estrogen receptors: an overview from different perspectives. Methods Mol Biol 2016;1366:1–10.

57Simpson ER: Role of aromatase in sex steroid action. J Mol Endocrinol 2000;25:149–156.

58Deslyper JP, Verdonck L, Vermeulen: A Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Met 1985;61:564–571.

59Sxymczak J, Millewicz A, Thijssen JHH, Blankstein MA, Daroszewski J: Concentration of sex steroids in adipose tissue after menopause. Steroids 1998;62:319–321.

60Blouin K, Richard C, Brochu G, Hould FS, Lebel S, Marceau S, et al: Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men. J Endocrinol 2006;191:637–649.

61World Health Organization (WHO). Obesity and Overweight. Fact sheet 2016 . Geneva, WHO, 2016. http://www.who.int/mediacentre/factsheets/fs311/en/.

62Eriksson J, Haring R, Grarup N, Vandenput L, Wallaschofski H, Lorentzen E, et al: Causal relationship between obesity and serum testosterone status in men: a bi-directional mendelian randomization analysis. PLoS One 2017;12:e0176277.

63De Maddalena C, Vodo S, Petroni A, Aloisi AM: Impact of testosterone on body fat composition. J Cell Physiol 2012;227:3744–3748.

64Michalakis K, Mintziori G, Kaprara A, Tarlatzis BC, Goulis DG: The complex interaction between obesity, metabolic syndrome and reproductive axis: a narrative review. Metabolism 2013;62:457–478.

65Morelli A, Sarchielli E, Comeglio P, Filippi S, Vignozzi L, Marini M, et al: Metabolic syndrome induces inflammation and impairs gonadotropin-releasing hormone neurons in the preoptic area of the hypothalamus in rabbits. Mol Cell Endocrinol 2014;382:107–119.

66Sarchielli E, Comeglio P, Squecco R, Ballerini L, Mello T, Guarnieri G, et al: Tumor necrosis factor-α impairs kisspeptin signaling in human gonadotropin-releasing hormone primary neurons. J Clin Endocrinol Metab 2017;102:46–56.

67Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al: American association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice guidelines for medical care of patients with obesity executive summarycomplete guidelines available at https://www.aace.com/publications/guidelines. Endocr Pract 2016;22:842–884.

68Camacho EM, Huhtaniemi IT, O’Neill TW, Finn JD, Pye SR, Lee DM, et al: Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: longitudinal results from the European Male Ageing Study. Eur J Endocrinol 2013;168:445–455.

69Corona G, Rastrelli G, Monami M, Saad F, Luconi M, Lucchese M, et al: Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013;168:829–843.

70Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al: Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.

71Haider A, Yassin A, Doros G, Traish AM, Saad F: Reductions of weight and waist size in 362 hypogonadal men with obesity grades I to III under long-term treatment with testosterone undecanoate (TU): observational data from two registry studies. Endocr Rev 2014;35:21–24.

72Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al: Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Invest 2016;39:967–981.

73Corona G, Giagulli VA, Maseroli E, Vignozzi L, Aversa A, Zitzmann M, et al: Therapy of endocrine disease: testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol 2016;174:R99–R116.

74Traish AM: Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes 2014;21:313–322.

75Zurlo F, Larson K, Bogardus C, Ravussin E: Skeletal muscle metabolism is a major determinant of resting energy expenditure. J Clin Invest 1990;86:1423–1427.

76Travison TG, Basaria S, Storer TW, Jette AM, Miciek R, Farwell WR, et al: Clinical meaningfulness of the changes in muscle performance and physical function associated with testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 2011;66:1090–1099.

77NCT02672592. Effects of Interleukin-1 Beta on Low Testosterone Levels in Men with Obesity and Metabolic Syndrome (TestIL). https://clinicaltrials.gov/ct2/show/NCT02672592.

78Pelusi C, Giagulli VA, Baccini M, Fanelli F, Mezzullo M, Fazzini A, et al: Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: a randomized, double-blind, placebo-controlled study. PLoS One 2017;12:e0183369.

79Bojesen A, Høst C, Gravholt CH: Klinefelter’s syndrome, type 2 diabetes and the metabolic syndrome: the impact of body composition. Mol Hum Reprod 2010;16:396–401.

80Calogero AE, Giagulli VA, Mongioì LM, Triggiani V, Radicioni AF, Jannini EA, et al: Klinefelter syndrome: cardiovascular abnormalities and metabolic disorders. J Endocrinol Invest 2017;40:705–712.

81Miller KK: Androgen deficiency: effects on body composition. Pituitary 2009;12:116–124.

82Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al: International Agency for Research on Cancer (IARC). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, IARC, 2017. globocan.iarc.fr.

83Hamilton EJ, Gianatti E, Strauss BJ, Wentworth J, Lim-Joon D, Bolton D, et al: Increase in visceral and subcutaneous abdominal fat in men with prostate cancer treated with androgen deprivation therapy. Clin Endocrinol (Oxf) 2011;74:377–383.

84Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al: Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599–603.

85Owen PJ, Daly RM, Livingston PM, Fraser SF: Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis 2017;20:137–145.

86Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al: Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008;112:2188–2194.

87Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M: Guidelines on male hypogonadism. Eur Assoc Urol 2015. https://uroweb.org/guideline/male-hypogonadism/ (accessed: April 18, 2019).

88Elbers JM, Asscheman H, Seidell JC, Gooren LJ: Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 1999;276(2 Pt 1):E317–E325.

89Gooren LJ: Management of female-to-male transgender persons: medical and surgical management, life expectancy. Curr Opin Endocrinol Diabetes Obes 2014;21:233–238.

90Traish AM, Gooren LJ: Safety of physiological testosterone therapy in women: lessons from female-to-male transsexuals (FMT) treated with pharmacological testosterone therapy. J Sex Med 2010;7:3758–3764.

91Velho I, Fighera TM, Ziegelmann PK, Spritzer PM: Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. Andrology 2017;5:881–888.

92Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al: The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 2014;171:P1–P29.

93Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, et al: Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab 2013;98:E628–E637.

94Pasquali R, Zanotti L, Fanelli F, Mezzullo M, Fazzini A, Morselli Labate AM, et al: Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective. J Clin Endocrinol Metab 2016;101:2013–2022.

95Poddar M, Chetty Y, Chetty VT: How does obesity affect the endocrine system? A narrative review. Clin Obes 2017;7:136–144.

96Escobar-Morreale HF, San Millán JL: Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007;18:266–272.

97Bhasin S, Storer TW, Berman N, Callegari C, Clevenger B, Phillips J, et al: The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N Engl J Med 1996;335:1–7.

98Birzniece V: Doping in sport: effects, harm and misconceptions. Intern Med J 2015;45:239–248.

99Kirchengast S: Gender differences in body composition from childhood to old age: an evolutionary point of view. J Life Sci 2010;2:1–10.

100Larsson I, Lissner L, Samuelson G, Fors H, Lantz H, Näslund I, et al: Body composition through adult life: Swedish reference data on body composition. Eur J Clin Nutr 2015;69:837–842.

101Vandewalle S, Taes Y, Fiers T, Toye K, Van Caenegem E, Roggen I, et al: Associations of sex steroids with bone maturation, bone mineral density, bone geometry, and body composition: a cross-sectional study in healthy male adolescents. J Clin Endocrinol Metab 2014;99:E1272–E1282.

102Vermeulen A, Kaufman JM, Giagulli VA: Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J Clin Endocrinol Metab 1996;81:1821–186.

Vito Angelo Giagulli

Outclinic Patients for Endocrinology and Metabolic Diseases, Conversano Hospital

Via De Amicis 30

IT–70014 Conversano (Ba) (Italy)

E-Mail vitogiagulli@alice.it